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Abstract
Background: An arteriovenous fistula (AVF) is considered the vascular access of choice, but uncertainty exists about the
optimal time for its creation in pre-dialysis patients. The aim of this study was to determine the optimal vascular access
referral strategy for stage 4 (glomerular filtration rate ,30 ml/min/1.73 m
2) chronic kidney disease patients using a decision
analytic framework.
Methods: A Markov model was created to compare two strategies: refer all stage 4 chronic kidney disease patients for an
AVF versus wait until the patient starts dialysis. Data from published observational studies were used to estimate the
probabilities used in the model. A Markov cohort analysis was used to determine the optimal strategy with life expectancy
and quality adjusted life expectancy as the outcomes. Sensitivity analyses, including a probabilistic sensitivity analysis, were
performed using Monte Carlo simulation.
Results: The wait strategy results in a higher life expectancy (66.6 versus 65.9 months) and quality adjusted life expectancy
(38.9 versus 38.5 quality adjusted life months) than immediate AVF creation. It was robust across all the parameters except
at higher rates of progression and lower rates of ischemic steal syndrome.
Conclusions: Early creation of an AVF, as recommended by most guidelines, may not be the preferred strategy in all pre-
dialysis patients. Further research on cost implications and patient preferences for treatment options needs to be done
before recommending early AVF creation.
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Introduction
The burden of chronic kidney disease (CKD) continues to
increase, with 571,414 patients in the end-stage renal disease
(ESRD) program in the United States in 2009 [1]. The majority of
these patients, 398,861, are on hemodialysis. An even greater
number of patients have advanced kidney failure with a
glomerular filtration rate less than 30 ml/min/1.73 m
2 (Stage 4
CKD) [2]. In the United States alone, it is estimated that 0.35% of
the adult population has stage 4 CKD, which translates into more
than 800,000 people. In 2009, 116,395 CKD patients progressed
to ESRD and started hemodialysis in the United States [1].
Thearteriovenousfistula (AVF) has been identified astheoptimal
vascularaccessforhemodialysispatientsbasedonimprovedsurvival
and fewer complications as compared to arteriovenous grafts (AVG)
and tunneled centralvenous catheters (CVC) [3].Despite this,more
than 80% of incident hemodialysis patients start with a CVC as
their vascular access[1]. Timely creation ofan AVFbeforethe need
for dialysis therapy may allow adequate time for the fistula to
mature aswellasprovidesufficienttimetoperformanothervascular
access procedure if the first attempt fails, thus obviating the need for
a CVC, though firm evidence for the same is lacking [4,5]. Hence,
most guidelines recommend assessment of patients for access
creation at the CKD 4 stage [5–9].
However, early AVF creation is not without problems. A small
number of patients may develop ischemic steal syndrome from
arterial ischemia in the distal limb or develop high output heart
failure. Both of these complications usually require AVF ligation
[10,11]. In addition, early AVF creation, prior to dialysis, will
likely result in many patients undergoing unnecessary surgery since
most stage 4 CKD patients are much more likely to die than to
actually develop ESRD and require dialysis [12]. Lastly, greater
than 25% of AVF may never mature enough to be used
functionally [13].
Thus creation of an AVF when a patient has stage 4 CKD but is
not yet on dialysis has both risks and potential benefits. There are
no validated prediction models to determine which patients will
progress to ESRD and thus should have an AVF created.
Therefore, patients in stage 4 CKD have two options; they can
either proceed with early AVF creation or start dialysis with a
CVC and proceed with AVF later. We used a decision- analytic
model to compare these two treatment options faced by patients
with stage 4 CKD. The model estimated survival as well as
quality-adjusted survival.
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The Decision Model
We used a Markov model to compare two treatment strategies
for stage 4 CKD patients: (1) AVF strategy and (2) Wait strategy.
In the model, hypothetical cohorts of patients are followed for the
remainder of their lifetimes [14]. With each monthly ‘cycle’ of the
model, patients may move between several different health states
(e.g. CKD stage 4 with no AVF, CKD stage 4 with AVF, Dialysis
with CVC, Dialysis with AVF, death) according to the occurrence
of clinical events (e.g. progression to dialysis, development of heart
failure due to AVF, etc). The probabilities that each of these events
occurs was determined using the best available data from the
literature. Because some of the transition probabilities depend on
the time since entering a state (such as mortality after starting
dialysis), we created ‘‘tunnel’’ states which are essentially copies of
a state that track the length of time spent in the state [15].
By simulating outcomes in large numbers of identical patients,
the average accumulated survival time with the two treatment
strategies may be estimated. For our base case analysis, we chose a
70-year-old patient with CKD stage 4, because the 65–74 year age
group is the fastest growing segment in the dialysis population [1].
It also represents a cohort where clinical equipoise regarding the
optimal strategy is the greatest [16].
Our decision model (Figure 1) evaluated the following two
treatment strategies:
1. AVF Strategy: CKD stage 4 patients get referred for an AVF;
and
2. WaitStrategy: CKDstage 4 patientsare not referred foranAVF.
When they reach the point of starting dialysis, they get a CVC as
their vascular access and are then referred for AVF surgery.
During each cycle of the model (1 month in this analysis),
hypothetical patients in any given health state are at risk of several
events, which may result in transitions to other health states. For
certain health states, we created ‘‘tunnel’’ states to force patients to
remain in that state for a fixed number of cycles (e.g. to account for
a three-month maturation period for AVF). Stage 4 CKD patients
may progress to dialysis; CKD or dialysis patients with an AVF
may develop heart failure or ischemic steal syndrome; patients
with a CVC may develop central vein stenosis; death may occur
while they are still in CKD stage 4 or while they are on dialysis.
Assumptions
The base case was that of a 70 year old man with CKD stage 4.
We assumed that the only choice of renal replacement therapy
(RRT) for this patient was hemodialysis; peritoneal dialysis and
renal transplantation were not considered in this analysis.
In the AVF strategy:
1. All patients with CKD stage 4 would be referred for an
AVF; it would take 2 months to create an AVF and 3
months for it to mature and be functional.
2. If an AVF failed, another attempt to make an AVF would
not be made.
3. If a patient with an AVF developed CHF or steal, the AVF
would be ligatedin the samemonth.Hence heart failureand
steal syndrome were modeled as temporary health states.
In the wait strategy:
1. All CKD 4 patients progressing to need dialysis would start
with a CVC.
2. Once on dialysis, they would all be referred to get an AVF,
with the same waiting and maturation period as above.
3. During the 2 cycles of waiting to get AVF surgery, a
proportion of patients would decide not to have an AVF
and remain on dialysis with a CVC.
Probabilities
Estimates and plausible ranges of event probabilities were
obtained from published articles and expert opinion (Table 1).
Both deterministic threshold analyses and probabilistic sensitivity
analyses were performed, as described below.
We identified 8 studies in the literature on mortality and
progression to ESRD for stage 4 CKD patients [12,17–23]
(Table 2). The rates of progression varied from a low of 4.27 per
100 person-years from a cardiac database [12] that likely had
many patients with ischemic nephropathy, to a high of 14.3 per
100 person-years [20] from a nephrology database that had a
significant proportion of proteinuric patients at high risk for
progression. For our base case we used data from O’Hare et al
[21] (9.31 per 100 person-years), since they provided data for
patients aged 65 to 74 years. The lowest and highest rates of
progression from the 8 studies were used in the sensitivity analyses.
The mortality rate for stage 4 CKD patients ranged from a low of
4.5 per 100 person-years to a high of 33.45 per 100 person years in
the same 2 studies [12,20]. As for progression, we used data from
the O’Hare study [21], (mortality rate 11.68 per 100 person-years)
with the extreme values used for sensitivity analyses.
Figure 1. Schematic representation of the decision-analysis model.
doi:10.1371/journal.pone.0028453.g001
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patients starting dialysis with a CVC or fistula [24–29] (Table 3).
The two studies in prevalent patients were published in 2001 and
2002, comprised younger patients (mean age ,60 yrs), and had
mortality rates of 7.29 to 13 per 100 person-years for patients with
an AVF and 15.16 to 23 per 100 person-years for patients with
CVC [25,27]. In contrast, the more recent studies included older,
incident patients with higher mortality rates [24,26,28,29]. The
mortality rate in patients with CVC, however, was approximately
1.5 to 2 times that of patients with an AVF in all the studies [24–
29]. We used data from Xue et. al. for our base case, since that
study provided separate mortality rates according to access type
for the first 90 days of dialysis and thereafter as well as included
elderly patients in the 65–74 age range [29]. A tunnel state was
created to account for the fact that the mortality rate is
significantly higher in the first three months of dialysis before it
levels off.
Rates of fistula failure were obtained from a Dutch prospective
study [30]. Fistula failure rates due to the loss of fistula patency
before cannulation were used to model failure rates in the CKD
stage. Functional failure, which refers to loss of fistula patency after
cannulation, was used to model failure rates in the dialysis states.
We incorporated secondary fistula failure rates, which include
intervening manipulations designed to re-establish or maintain the
Table 1. Probabilities and Utilities.
Variables Best Estimate Range (for sensitivity analysis) Distribution Reference
Rate of progression to ESRD 0.0076 0.00356–0.019 Lognormal 19
CKD stage 4 mortality 0.0097 0.00375–0.0279 Lognormal 19
Mortality on dialysis with CVC in first three months 0.042 0.0126–0.0503 Lognormal 27
Mortality on dialysis with CVC after three months 0.020 0.0126–0.0503 Lognormal 27
Mortality on dialysis with AVF in first three months 0.018 0.0061–0.0232 Lognormal 27
Mortality on dialysis with AVF after three months 0.013 0.0061–0.0232 Lognormal 27
Patient refusal for an AVF 0.0467 0.01–0.1 Beta 29
Central vein stenosis 0.017 0.001–0.05 Beta 29
Heart Failure due to AVF 0.0004 0.001–0.09 Lognormal Expert opinion
Mortality due to heart failure 0.012 0.01–0.5 Beta Expert Opinion
Surgical mortality 0.001 0.0001–0.005 Beta Expert opinion
Ischemic steal syndrome 0.0504 0.001–0.09 Lognormal 29
AVF Failure: first three months 0.025 0–0.9 Lognormal 28
AVF Failure: after three months 0.016 0–0.9 Lognormal 28
AVF failure on dialysis 0.010 0–0.9 Lognormal 28
Utility of CKD stage 4 without AVF 0.62 0.40–0.84 Triangular 31
Utility of CKD stage 4 with AVF 0.62 0.40–0.84 Triangular 31
Utility of dialysis 0.51 0.20–0.82 Triangular 31
doi:10.1371/journal.pone.0028453.t001
Table 2. Summary of literature on mortality and progression to ESRD in CKD stage 4.
Study Mean age (years) GFR (ml/min) Progression to ESRD Mortality Population
Keith (2001) 73.6613.6 15–29 19.9%
* 45.7%
* Large HMO
Go (2004) 70.1614.5 15–29 11.36 per 100 PY
{ Large HMO
Patel (2005) 70.0610.0 15–29 14.2 per 100 PY 20.1 per 100 PY Veterans
O’Hare (2007) 65–74 15–29 9.31 per 100 PY 11.68 per 100 PY Veterans
O’Hare (2007) 75–84 15–29 6.31 per 100 PY 15.39 per 100 PY Veterans
Roderick (2009) 83.267.1 ,30 19–29 per 100 PY UK General Practice
Keough-Ryan (2008) 69.2613.2 ,30 4.27 per 100 PY 33.45 per 100 PY Post acute cardiac event
Levin (2008) 66.8614.5 ,30 14.3 per 100 PY 4.5 per 100 PY Referred population
Conway (2009) Median 71.6 ,30 3.8%
{ 10.4%
{ Referred population
*crude data in percentages, over 66 months of follow up.
{crude 1 year data in percentages.
{Age-Standardized Rates.
PY: patient-years.
HMO: Health Maintenance Oraganization.
doi:10.1371/journal.pone.0028453.t002
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fistula failure rates in the first 3 months after creation which
plateau thereafter. The probabilities of developing steal syndrome
and central vein stenosis, and of refusing dialysis, were derived
from a cross-sectional study [31]. Since there were only case
reports and no summary estimates of the incidence rate of high
output heart failure with AVF, it was assumed to be 5 per 1000
patient-months based on expert opinion (SH, GK). Since there
were no data on operative mortality rate for an AVF creation or
ligation surgery, it was similarly assumed to be 1 in 1000 based on
expert opinion (SH, GK). Both of these subjective estimates were
subjected to sensitivity analysis.
Outcomes
Life expectancy with each strategy was calculated based on the
average accumulated survival time. Quality-adjusted life expec-
tancy was calculated by weighting the time spent in each state
with the preference-based utility of that state [32]. The utilities
for the health states of CKD stage 4 and dialysis were obtained
from a Canadian study that measured the Short Form-6D (SF-
6D) and Health Utilities Index Mark 3 (HUI), the latter of which
was used [33]. We assumed that an AVF would not result in a
significant disutility for CKD stage 4 patients. We also assumed
that utilities for dialysis patients with CVC and AVF would be the
same; sensitivity analyses were performed to test these assump-
tion. Utilities assigned to each month were the average of those
for the patient’s health state at the beginning and end of the
month [34].
Analysis
The analysis was done using a Markov cohort method with
100,000 patients. Model verification (debugging) was done by
building up the model from simple to more complex, checking
each step visually, examining the state probabilities from the
cohort analysis, exploring certain extreme values and doing a
sensitivity analysis on all variables. The model was calibrated by
comparing simulated events (mortality for dialysis patients in the
model) to observed ones (from the USRDS report) [1]. A
probabilistic sensitivity analysis was done by assigning probability
distributions around model parameters and by using Monte Carlo
simulation [35] (table 4). All analysis was done using TreeAge Pro
2008 software (version 1.3.1, Williamstown, MA) and JMP
(version 8.0, SAS Inc., Cary, NC).
Results
Base Case Analysis
The results of the base case analysis showed that the wait
strategy resulted in a slightly higher life expectancy (66.55 vs 65.9
months) and quality-adjusted life expectancy (QALE) (38.89 vs.
38.49 quality-adjusted life months) as compared to the AVF
strategy (Table 5).
Table 3. Summary of literature on difference in mortality with CVC and AVF.
Study Mean age
Mortality with
AVF (per 100 PY)
Mortality with
CVC (per 100 PY) Population
Dhingra (2001) Diabetes 59.2 13
* 22
* Prevalent, DMMS Wave 1
Dhingra (2001) No Diabetes 59.2 11
* 23
* Prevalent, DMMS Wave 1
Pastan (2002) 58.360.2 7.29 15.16 Prevalent ESRD Network 6
Xue (2003) First 90 days ,75 28.8 60.4 Incident Medicare
Xue (2003) Next 9 months ,75 21.6 52.8 Incident Medicare
Polkinghorne (2004) 61 (range 48–71) 8.6 26.1 Incident
Moist (2008) 68 (median) HR 1.6
{ Incident
Bradbury (2009) 62.5615 9.96
{ 53.62
{ Incident, DOPPS I & II
*Adapted from Adjusted patient survival data.
{Hazard ratio, compared to mortality with AVF.
{Six month follow up data.
PY: patient-years.
doi:10.1371/journal.pone.0028453.t003
Table 4. Probability Distributions and parameter estimates
used in the Probabilistic Sensitivity Analysis.
Variables Distribution Parameters
Rate of progression to ESRD Lognormal m=22.333;s=0.406
CKD stage 4 mortality Lognormal m=22.577;s=0.415
Mortality on dialysis with CVC
in first three months
Lognormal m=25.473;s=0.604
Mortality on dialysis with CVC
after three months
Lognormal m=26.215;s=0.759
Mortality on dialysis with AVF
in first three months
Lognormal m=26.320;s=0.901
Mortality on dialysis with AVF
after three months
Lognormal m=26.645;s=0.724
Patient refusal for an AVF Beta r=28;n=599
Central vein stenosis Beta r=10;n=599
Heart Failure due to AVF Lognormal m=29.210;s:0 . 6 0 1
Mortality due to heart failure Beta r=5;n=404
Surgical mortality Beta r=1;n=1000
Ischemic steal syndrome Lognormal m=22.987;s=0.768
AVF Failure: first three months Lognormal m=23.689;s=1.010
AVF Failure: after three months Lognormal m=24.135;s=0.970
AVF failure on dialysis Lognormal m=24.605;s=1.177
Utility of CKD stage 4 Triangular low=0.40; most
likely=0.62; high=0.84
Utility of dialysis Triangular low=0.20; most
Likely=0.51; high=0.82
doi:10.1371/journal.pone.0028453.t004
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Multiple one-way sensitivity analyses were carried out for all the
variables entered in the model. The optimal strategy changed at
very high rates of progression of CKD to dialysis as well at lower
rates of steal syndrome than used in the base case analysis. When
the rate of progression was higher than 0.01126 (corresponding to
14.5 per 100 patient-years), the optimal strategy was to refer
patients for AVF creation (Figure 2). The additional LE and
QALE obtained at the highest rate of progression used in the
sensitivity analysis were 0.05 and 0.03 months respectively.
Similarly, the optimal strategy changed to AVF creation when
the probability of steal syndrome was lower than 0.023. The
additional LE and QALE obtained with the AVF strategy when
there was no steal syndrome were 0.5 and 0.3 months respectively.
If the utility of CKD stage 4 patients with an AVF was higher than
0.7 whilst maintaining the utility of CKD stage 4 patients without
an AVF at 0.62, the optimal strategy reverted to the AVF strategy.
When the fistula failure rates were changed to zero, the optimal
strategy did not change. The optimal strategy is also otherwise
robust across the range of probabilities tested for all other
parameters (Table 1).
A two-way sensitivity analysis with respect to the probabilities of
progression and steal syndrome isshowninFigure 3.It demonstrates
that as the rate of progression to dialysis increases, the AVF strategy
becomes optimal despite increasing probability of steal syndrome.
Incremental outcomes from the probabilistic sensitivity analysis,
expressed as a difference of quality adjusted life expectancy
obtained between the two strategies, were obtained using a Monte
Carlo simulation. The probability that the wait strategy is optimal
was 91.7% (Figure 4).
Discussion
In this decision analysis, we have shown that the wait strategy is
the optimal strategy for our base case of a 70-year old patient with
stage 4 CKD. However, the gains in life expectancy and quality-
adjusted life expectancy are likely to be less than one month. The
analysis was robust across the range of values for most variables in
the model, with the possible exception of the rate of progression to
ESRD and the rate of steal syndrome.
These results suggest that recommendations of the Fistula First
Breakthrough Initiative and the various society guidelines, to










Wait 66.55 0.65 38.89 0.50
AVF 65.90 - 38.49 -
doi:10.1371/journal.pone.0028453.t005
Figure 2. One way sensitivity analysis based on rate of progression of CKD stage 4 to dialysis: This demonstrates that the wait
strategy results in a higher quality-adjusted life expectancy at lower rates of progression and the AVF strategy results in a higher
quality adjusted life expectancy at higher rates of progression of CKD to dialysis.
doi:10.1371/journal.pone.0028453.g002
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apply all patients. It might especially be prudent to wait in patients
similar to our base case, who have a slow rate of progression and
high rates of competing events. Indeed, it may not be optimal to
wait in patients with a high rate of progression (such as proteinuric
diabetic nephropathy) though the quality-adjusted life expectancy
gained by early fistula creation in such patients is less than one
month. Additionally, the assumption underlying these conclusions
is that the patients who wait will get an AVF soon after initiation of
dialysis, and will not be exposed to the deleterious effects of a CVC
beyond 3 months. The strategy of initiating dialysis with a catheter
in appropriate patients has been suggested before [36] and our
study helps to quantify the benefit of such a decision. Also,
conversion from a CVC to AVF has been reported to be
associated with an improved survival [24] and hospitalization risk
is also higher for patients who continue with a CVC compared to
those who convert from a CVC to an AV access [37]. It could be
argued that patients who start dialysis with a CVC may not want
to have another surgery for AVF creation, but we incorporated
that by inserting a parameter for higher patient refusal for AVF in
the wait strategy.
In the present study, we are not suggesting that patients should
start with and remain on a CVC, or that CVCs are superior to
AVFs as vascular access. It has been suggested, however, that in
the elderly population, and in octogenarians specifically, that an
assessment of life expectancy and quality of life should be made
while planning for vascular access [36,38].
The model construction itself had some limitations. We
considered only hemodialysis as an option for our base case
analysis. While this is the most common initial treatment modality
for patients fitting our base case [39], some patients will indeed opt
for peritoneal dialysis or kidney transplantation. This may limit the
generalizability of our findings to all stage 4 CKD patients. We
also assumed that only one attempt would be made to create an
AVF. This assumption resulted in most patients having a failed
AVF by the time they started hemodialysis. In clinical practice, it
could be argued that many of these patients would have had a
second attempt at AVF creation. In our cross-sectional study, we
found that a median of two attempts (range, 1 to 4) were made at
AVF creation [31]. However, in sensitivity analysis, the wait
strategy remained optimal despite an AVF failure rate of zero,
suggesting that incorporating multiple attempts will not change the
result. Lastly, we did not include AV grafts (AVG) as an option for
vascular access. AVGs have been compared to AVFs in a decision
analysis and were reported to have a lower median survival, albeit
less than expected, by 2.6 months [40].
There were limitations related to the data sources used in the
model. Since no randomized controlled trial has ever been done to
compare outcomes between AVF and CVC in dialysis patients, we
had to rely on data from administrative sources to obtain estimates
of mortality rates in patients with CVC and AVF. However, many
incident dialysis patients with a CVC in these databases may have
been patients with acute renal failure in whom the mortality rate
may be much higher than for patients with known renal disease
and a planned start with a CVC. More accurate data reflecting
lower mortality with CVC would, however, make the results
favoring the wait strategy even stronger. We used post-interven-
tion figures from a Dutch study in our estimates of fistula failure
rates [30]. These figures might be optimistic in North American
situations since European centers have a significantly higher
prevalence of AVF compared to CVCs [41]; however lower fistula
survival rates would make the wait strategy even more favorable.
We chose wait times for access creation based on local data,
however this may vary at other centres and novel approaches such
as direct nephrologist selection for operation have resulted in
shorter waiting times for access creation [42].
There were limitations related to the utilities in the model. We
assumed that the utility for a patient with CKD stage 4 with an
AVF would be the same as that of a patient with CKD stage 4 who
did not have a fistula. Although the optimal strategy would change
if having an AVF increased the utility for a CKD stage 4 patient,
this is an unlikely scenario. In addition, we assumed that the utility
of a dialysis patient with a CVC would be the same as for a dialysis
patient with an AVF. Indeed, despite nephrologists’ opinion of the
AVF being the optimal access, interviews with patients who have
refused an AVF suggest that they do not always focus on long-term
mortality benefit, but rather day-to-day use and quality of life with
a vascular access [43]. Although sensitivity analyses conducted on
this parameter was robust, further studies are needed to correctly
elucidate preference utilities in CKD and dialysis patients with
different vascular access.
We did not assess the comparative costs of the two strategies,
nor did we perform an incremental cost-effectiveness analysis.
Because of the higher number of surgeries in the AVF strategy and
the fact that the cost of an AVF surgery is higher than that of CVC
insertion, it is likely that the cost would be higher in the AVF
strategy, thus making the wait strategy dominant (more QALYs at
lower cost) over the AVF strategy.
In summary, this analysis suggests that the optimal strategy in a
typical elderly stage 4 CKD patients should be to wait and start
with a CVC when required followed by AVF creation. This
strategy was robust across most sensitivity analysis. However, it
might not be optimal for patients with a very high probability of
progression to dialysis, such as patients with proteinuric diabetic
nephropathy. Further studies should be done to obtain more
precise estimates of progression and develop prediction rules for
progression of renal failure in CKD stage 4 which take competing
events of death into account.
Figure 3. Two-way sensitivity analysis plotting rate of progres-
sion to dialysis and probability of steal: This demonstrates that
the wait strategy results in a higher quality-adjusted life
expectancy at lower rates of progression and lower proba-
blility of ischemic steal and the AVF strategy results in a higher
quality adjusted life expectancy at higher rates of progression
of CKD to dialysis and higher rates of ischemic steal.
doi:10.1371/journal.pone.0028453.g003
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